Journal article
Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis
Abstract
BACKGROUND: Venom immunotherapy (VIT) is a treatment with established efficacy for the prevention of repeated anaphylactic reactions in patients with Hymenoptera allergy, which also allows patients to discontinue carrying an EpiPen. Despite their merits, both treatments can have negative aspects potentially important to patients.
OBJECTIVE: We examined possible negative aspects of the EpiPen in comparison with VIT as perceived by patients.
Authors
Elberink JNGO; van der Heide S; Guyatt GH; Dubois AEJ
Journal
The Journal of Allergy and Clinical Immunology, Vol. 118, No. 3, pp. 699–704
Publisher
Elsevier
Publication Date
9 2006
DOI
10.1016/j.jaci.2006.03.049
ISSN
0091-6749